Respiratory Medicine
Volume 100, Issue 9 , Pages 1623-1632 , September 2006

Inhaled steroids improve quality of life in patients with steady-state bronchiectasis

  • Miguel A. Martínez-García

      Affiliations

    • Pneumology Unit, Requena General Hospital, Valencia, Spain
    • Corresponding Author InformationCorresponding author. Unidad de Neumología, Servicio de Medicina Interna, Hospital General de Requena, Paraje Casa Blanca s/n, 43230–Requena, Valencia, Spain. Tel.: +34962336972; fax: +34962336973.
    • ,
  • Miguel Perpiñá-Tordera

      Affiliations

    • Pneumology Service, La Fe University Hospital, Valencia, Spain
    • ,
  • Pilar Román-Sánchez

      Affiliations

    • Service of Internal Medicine, Requena General Hospital, Valencia, Spain
    • ,
  • Juan Jose Soler-Cataluña

      Affiliations

    • Pneumology Unit, Requena General Hospital, Valencia, Spain

Received 13 September 2005 ,Accepted 7 December 2005.

References 

  1. Cohen M, Sahn SA. Bronchiectasis in systemic diseases. Chest. 1999;116:1063–1074
  2. Barker AF. Bronchiectasis. N Engl J Med. 2002;246:1383–1393
  3. Gaga M, Bentley AM, Humbert M, et al. Increase in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax. 1998;53:685–691
  4. Watt AP, Brown V, Courtney J, et al. Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis. Thorax. 2004;59:231–236
  5. Richmann-Eisenstat JBY, Jorens PG, Hebert CA, Ueki I, Nadel JA. Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airways disease. Am J Physiol. 1993;264:413–418
  6. Ho JC, Tipoe G, Zheng L, et al. In vitro study of regulation of IL-6 production in bronchiectasis. Respir Med. 2004;98:334–341
  7. Tsang KW, Chan K, Ho P, et al. Sputum elastase in steady-state bronchiectasis. Chest. 2000;117:420–426
  8. Ellis DA, Thornley PE, Wightman AJ, Walter M, Chalmers J, Crofton JW. Present outlook in bronchiectasis: clinical and social study and review of factors influencing prognosis. Thorax. 1981;36:659–664
  9. Wilson CB, Jones PW, O’Leary CJ, Cole PJ, Wilson R. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med. 1997;156:536–541
  10. Martínez-García MA, Perpiñá M, Román P, Soler-Cataluña JJ. Determinants of quality of life in patients with clinically stable bronchiectasis. Chest. 2005;128:739–745
  11. Tsang KWT, Ho PL, Lam WK, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med. 1998;158:723–727
  12. Elborn JS, Johnston B, Allen F, Clarke J, McGarry J, Varghese G. Inhaled steroids in patients with bronchiectasis. Respir Med. 1992;86:121–124
  13. Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax. 2005;60:239–243
  14. Kolbe J, Wells A, Ram FSF. Inhaled steroids for bronchiectasis. In: Cochrane Library, vol. 1. Oxford: Update Software.CD000996; 2001.
  15. Global Initiative for Asthma. Global strategy for asthma Management and prevention NHLBI/WHO workshop report 2002. http://www.ginasthma.com
  16. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2002;10:685–692
  17. Naidich DP, McCauley DI, Khouri NF, Stitik PP, Siegelman SS. Computed tomography of bronchiectasis. J Comput Assist Tomogr. 1982;6:437–444
  18. Bhalla M, Turcios N, Aponte V, et al. Cystic fibrosis: scoring system with thin-section CT. Radiology. 1991;179:783–788
  19. Mahler DA, Weinberg DM, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement and physiologic correlation of two new clinical indexes. Chest. 1984;85:751–758
  20. Martínez-García MA, Perpiñá M, Román P, Soler-Cataluña JJ. Consistencia interna y validez de la versión española del St. George's Respiratory Questionnaire para su uso en pacientes con bronquiectasias clínicamente estables. Arch Bronconeumol. 2005;41:110–117
  21. Murria PR, Washington JA. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin Proc. 1975;50:339–344
  22. Roca J, Sanchos J, Agusti-Vidal A, et al. Spirometric referente values for a mediterranean population. Bull Eur Physiopathol Respir. 1986;22:217–224
  23. Jones PW, Quirk FH, Baveystock CM. The St. George's Respiratory Questionnaire. Respir Med. 1991;85(suppl B):25–31
  24. Witek TJ, Mahler DA. Meaningfull effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol. 2003;56:248–255
  25. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728–1733
  26. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Malen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J. 2000;320:1297–1303
  27. Suissa S, Ersnt P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343:332–336
  28. Wilson CB, Jones PW, O’Leary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the HRQoL of patients with bronchiectasis. Eur Respir J. 1997;10:1757–1760
  29. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Eng J Med. 2000;343:1902–1909

PII: S0954-6111(05)00525-1

doi: 10.1016/j.rmed.2005.12.002

Respiratory Medicine
Volume 100, Issue 9 , Pages 1623-1632 , September 2006

Article Tools

* Image Usage & Resolution